Drugs for neglected diseases: A failure of the market and a public health failure?

Tropical Medicine and International Health

Volumn 6, Issue 11, 2001, Pages 945-951

  Trouiller, Patrice ^a   Torreele, Els ^b   Olliaro, Piero ^c   White, Nick ^d   Foster, Susan ^e   Wirth, Dyann ^f   Pécoul, Bernard ^g  

^a UNIV GRENOBLE ALPES   (France)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d MAHIDOL UNIVERSITY   (Thailand)

^e BOSTON UNIVERSITY   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

Medicines; Neglected diseases; Pharmaceutical market; Public policy

Indexed keywords

DRUG;

DISEASE TREATMENT; PHARMACEUTICAL INDUSTRY; PUBLIC HEALTH; RESEARCH AND DEVELOPMENT;

ARTICLE; DEVELOPING COUNTRY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDUSTRY; DRUG USE; ECONOMIC DEVELOPMENT; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; HUMAN; HUMAN RIGHTS; INFECTION; ORGANIZATION AND MANAGEMENT; POLITICS; PUBLIC HEALTH; REGULATORY MECHANISM; TECHNOLOGY;

COMMUNICABLE DISEASES, EMERGING; DRUG AND NARCOTIC CONTROL; HEALTH CARE SECTOR; HEALTH POLICY; HEALTH PRIORITIES; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; LEGISLATION, DRUG; RESEARCH; WORLD HEALTH;

EID: 0034771740     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3156.2001.00803.x     Document Type: Article

References (28)

1. Patents in a genetic age
2. Will patents on human genes encourage research or stifle it?
3. AIDS: Patent rights versus patient's rights
4. New drug developments in the United States from 1963 to 1992
5. Political economy of technology transfer
6. Returns to R & D on new drug introduction in the 1980s
7. Orphan drugs: The United States experience
8. Can patents deter innovation? The anticommons in biomedical research
9. Call for more reliable costs data on clinical trials
10. The normalisation of the international market for pharmaceuticals: Future impacts in emerging markets
11. Access to essential drugs in poor countries. A lost battle?
12. Dilemmas in drug development for tropical diseases, experiences with praziquantel
13. Helping the world's poorest
14. Recherche et développement pharmaceutiques en matière de maladies transmissibles dans la zone intertropicale
15. Is orphan drug status beneficial to tropical disease control? Comparison of the American and future European orphan drug acts
16. Drug development output from 1975 to 1996: What proportion for tropical diseases?
17. Globalization and harmonization of regulatory issues: The WHO perspective of developing countries' needs and perspectives
18. Global treatment and access to medicines: AIDS drugs in Thailand